
    
      SPOCS is an international, multicenter, prospective observational cohort study with bi-annual
      follow-up over 3-years maximum follow-up of patients with SLE confirmed by American College
      of Rheumatology (ACR) or Systemic Lupus International Collaborating Clinics (SLICC)
      classification criteria, who have moderate-to-severe disease by SLEDAI-2K criteria (Modified
      SLEDAI-2K score ≥4 and/or SLEDAI-2K score ≥6 points, at least one life-time positive serology
      of anti-nuclear antibody (ANA) or double-stranded deoxyribonucleic acid antibody (dsDNA), and
      6-month minimum treatment duration with systemic SLE treatment beyond NSAIDS and analgesics.
      Participants will be followed as per local routine clinical practice. SPOCS is an
      observational study with no requirement for protocolized treatment interventions.
    
  